OTC Markets
Prev Close 0.08
Day Low/High 0.08 / 0.08
52 Wk Low/High 0.05 / 0.14
Exchange OTC Markets
Shares Outstanding 44.37B
Market Cap 3.59M
Div & Yield N.A. (N.A)

Latest News

GeoVax Receives

GeoVax Receives "Allowed To Proceed" Notice For Testing Adjuvanted HIV Vaccine

Phase 1 Clinical Trial to Begin in April with NIH Support

GeoVax Labs, Inc. Announces Private Offering Of Common Stock And Warrants

GeoVax Labs, Inc. Announces Private Offering Of Common Stock And Warrants

Offering Expected to Be Completed by January 31, 2012

GeoVax Labs' First Patient Inoculated In Phase 1/2 Clinical Trial For HIV/AIDS Therapeutic Vaccine

Important Milestone in Study of HIV-Infected Individuals Who Started Drug Treatment During Their First 18 Months of Infection

GeoVax Phase 2a Clinical Trial Completes Enrollment

Participants Demonstrating Neutralizing Activity that Blocks Infection

GeoVax Labs' CSO And Chairman Receive Academic Honors

CSO Harriet L. Robinson Honored as Distinguished Emeritus Faculty; Chairman David A. Dodd To Receive Alumni Award from Georgia State University

GeoVax $3.6 Million Award Increased To $4.4 Million By U.S. Government

Aggregate Total Award of $20.4 Million for Clinical Development of HIV/AIDS Vaccine

GeoVax Awarded $3.6 Million Grant By U.S. Government For Its HIV/AIDS Vaccine Program

U.S. Government Continues Support for Clinical Development of Adjuvanted Vaccine

GeoVax Initiates Third Site For Therapeutic Testing Of Its HIV Vaccine

Los Angeles-Based AIDS Research Alliance Selected as Site

GeoVax Trial Results Establish A New Benchmark For Preventative HIV Vaccine Model

Non Human Primate Study Demonstrates Unprecedented 70% Prevention of Infection

Article By GeoVax Labs CSO Featured In The Scientist

Dr. Harriet L. Robinson Outlines Progress Toward Development of an Effective HIV Vaccine

Expansion Of HIV/AIDS Vaccine Program Announced By GeoVax Labs, Inc.

Adjuvant Gives 70% Prevention of Infection in Primates

GeoVax Labs HIV/AIDS Vaccine Development Leadership To Be Highlighted During 2011 World Vaccine Congress

CSO To Review Progress of Clinical Trials and Vaccine Technology

Article By GeoVax Labs CEO Featured In October 15 Issue Of Genetic Engineering & Biotechnology News

CEO Robert T. McNally Assesses the Ongoing Search for an HIV Vaccine

GeoVax Labs Appoints Two Industry Veterans To Board Of Directors

Experience in Finance, Business Development and Healthcare Adds Depth to Board

GeoVax Labs, Inc. Reports Fourth Quarter And Year End 2009 Financial Results

Submits Therapeutic Vaccine IND and Awaits FDA Response

GeoVax Labs, Inc. Reports Data On Prototype Adjuvant - Supplemented HIV Vaccine Tested In Preclinical Animal Studies

Results From Study Using Non-human Primates Indicate 70% Level of Protection From Infection